candesartan cilexetil has been researched along with Diabetes Mellitus in 4 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Candesartan is a selective angiotensin II Type I (AT(1)) receptor blocker which binds tightly to, and dissociates slowly from the receptor." | 6.42 | Candesartan for the treatment of hypertension and heart failure. ( Ostergren, J, 2004) |
| "Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system." | 2.47 | Differential clinical profile of candesartan compared to other angiotensin receptor blockers. ( Cernes, R; Mashavi, M; Zimlichman, R, 2011) |
| " All of these were similar in design: i) a 4-week placebo run-in period, ii) a 4- to 6-week period (V1) with CC 8 mg once daily (od), after which the dosage was doubled if BP was not normalized (BP > 140/90 or BP >130/80 mmHg in diabetes), and iii) a 4- to 6-week period (V2) with CC 8 or 16 mg od." | 2.44 | Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials. ( Asmar, R; Féghali, RE; Nisse-Durgeat, S, 2007) |
| " Depending on the BP response, dosage of CC 8 mg was doubled at the follow-up visit if BP >or=140/90 mmHg." | 2.44 | [Efficacy of candesartan cilexetil in hypertensive patients with or without diabetes]. ( Asmar, R; El Féghali, R; Nisse-Durgeat, S, 2007) |
| "Candesartan is a selective angiotensin II Type I (AT(1)) receptor blocker which binds tightly to, and dissociates slowly from the receptor." | 2.42 | Candesartan for the treatment of hypertension and heart failure. ( Ostergren, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cernes, R | 1 |
| Mashavi, M | 1 |
| Zimlichman, R | 1 |
| Ostergren, J | 1 |
| Féghali, RE | 1 |
| Nisse-Durgeat, S | 2 |
| Asmar, R | 2 |
| El Féghali, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer[NCT06168487] | Early Phase 1 | 42 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for candesartan cilexetil and Diabetes Mellitus
| Article | Year |
|---|---|
Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Biphenyl Compounds; | 2011 |
Candesartan for the treatment of hypertension and heart failure.
Topics: Administration, Oral; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus; Double-Blind Method; Dr | 2004 |
Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl | 2007 |
[Efficacy of candesartan cilexetil in hypertensive patients with or without diabetes].
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus; Double-Blind Method; | 2007 |